Co-Authors
This is a "connection" page, showing publications co-authored by FUNDA MERIC-BERNSTAM and KIM-ANH DO.
Connection Strength
1.902
-
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
Score: 0.179
-
Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS One. 2015; 10(9):e0136851.
Score: 0.137
-
Epithelial to mesenchymal transition is associated with rapamycin resistance. Oncotarget. 2015 Aug 14; 6(23):19500-13.
Score: 0.137
-
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. 2015 Mar; 107(3).
Score: 0.132
-
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. Oncotarget. 2014 Sep 30; 5(18):8544-57.
Score: 0.129
-
Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin Cancer Res. 2014 Jul 15; 20(14):3870-83.
Score: 0.126
-
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.
Score: 0.124
-
High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat. 2013 Jan; 137(1):319-27.
Score: 0.114
-
Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res. 2012 Oct 26; 14(5):R138.
Score: 0.113
-
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res. 2012 Oct 15; 18(20):5816-28.
Score: 0.112
-
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012 Mar 15; 18(6):1777-89.
Score: 0.108
-
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011 Mar 01; 17(5):1082-9.
Score: 0.100
-
Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther. 2010 Oct; 9(10):2770-84.
Score: 0.098
-
Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010 Aug; 3(8):1026-34.
Score: 0.096
-
Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway. Mol Ther. 2014 Jul; 22(7):1310-1319.
Score: 0.031
-
Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. 2014 Feb; 23(2):316-23.
Score: 0.030
-
Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. Ann Oncol. 2013 Oct; 24(10):2522-2526.
Score: 0.030
-
Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer. 2013 Jan 01; 119(1):7-15.
Score: 0.028
-
Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res. 2012 Feb 15; 18(4):1109-19.
Score: 0.027
-
Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer. 2012 Mar 15; 118(6):1498-506.
Score: 0.026
-
Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011 Jul 01; 29(19):2628-34.
Score: 0.026